IRVINE, CA--(Marketwired - Apr 17, 2017) - Cannabis Science, Inc. (
"We are heading to Harvard Medical School shortly to present our cannabinoid findings and action plans to success at the Global Health Summit, these types of large land deals are at the heart of our growth and will certainly be a part of my presentation for the world to understand. This is certainly the strongest way to bring more of our formulations to market immediately and with due course FDA resolve. We have been releasing test products through the State by State initiatives in California though our partners and licensees, our next project for the Industrial Commercial Hemp Grow Initiatives, and of course our FDA drug development programs. This type of aggressive progress certainly gives us the insight required to continue down our path of accomplishments. There comes a point when you must sit back and look at what is going on with the industry and where you belong.
"We are certainly cementing our position as we continue pushing to get our critical ailment drug pipeline developed as quickly as possible. Cannabis Science, RCDU, and its Sovereign partners look to be one of the country's largest Industrial Commercial Hemp producers as this seeding schedule now encompasses 350 acres, all of which is scheduled to be planted at once on Sovereign lands in San Joaquin MBS and Douglas County. Each acre has the potential yield of up to 1,600 pounds per acre with wholesale prices ranging from 500 USD per pound. Potentially Cannabis Science, RCDU, Investors, and its Sovereign partners are looking at annual harvests yields grossing revenue several hundred million dollars. This is just the tip of the iceberg for Cannabis Science as we enter the farming aspect to supply product for our medicine development needs. With thousands of acres secured and verbal commitments on thousands more, Cannabis Science and its Sovereign partners are certainly underway in this fast-growing Industrial Commercial Hemp sector of the industry," stated, Cannabis Science Inc. President, CEO & Co-Founder Mr. Raymond C. Dabney.
About Cannabis Science, Inc. Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Cannabis Science, Inc. Dr. Allen Herman Chief Medical Officer (CMO) allen.herman@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Mr. Raymond C. Dabney President & CEO, Co-Founder raymond.dabney@cannabisscience.com Tel: 1-888-263-0832 Cannabis Science, Inc. Investor Relations Teresa Misenheimer Email: teresa@cannabisscience.com Tel: 1-888-263-0832
